US drug firm Mylan to buy Indian firm for $1.6 bn

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

The Pennsylvania-based Mylan said the all-cash buyout of Agila Specialities, which makes injectables, is expected to be completed in the fourth quarter of 2013 subject to regulatory approvals.

"The addition of Agila to our existing platform will immediately create a new, powerful global leader in this fast-growing, attractive market segment," said Mylan chief executive Heather Bresch in a statement on the company's website.

"It will accelerate our target of becoming a top-three global player in injectables."

Strides' group chief executive Arun Kumar said in a statement the sale will "maximise value for its shareholders".

The sale of Bangalore-based Agila ends months of speculation. Top drug maker Pfizer and Japan's Otsuka Holdings were seen as potential buyers, according to media reports.

Mylan's chief financial officer John Sheehan said the deal would "immediately enhance revenue and earnings growth".

Mylan will have more than 700 marketed injectable products and a global pipeline of more than 350 injectable products pending the approval, its president Rajiv Malik said.

The global generic injectable drugs market is expected to grow at an annual rate of 13 percent between 2011 and 2017, driven by patent expiries, which will outpace most other dosage forms, the US firm said.

add to favorites email to friend print save as pdf

Related Stories

Generic versions of plavix approved

May 18, 2012

(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

Profit at drugmaker Sanofi up 35 pct for 1st half

Jul 26, 2012

(AP) — Drugmaker Sanofi saw its net profit rise 35 percent in the first half of the year as it pushes into areas with long-term growth potential to off-set the expiration of profitable patents.

Generic boniva approved for osteoporosis

Mar 19, 2012

(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Ecolab buying Champion Technologies in $2.2B deal

Oct 12, 2012

Ecolab, the cleaning, food safety and pest-control services company, is buying the specialty chemical company Champion Technologies in a cash-and-stock deal valued at about $2.2 billion.

Global spending on drugs to slow through 2016

Jul 12, 2012

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

Recommended for you

Seniors successfully withdraw from meds

6 hours ago

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

Flu vaccine for expectant moms a top priority

Sep 18, 2014

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments